Controlled Delivery of Low-Dose Bone Morphogenetic Protein-2 Using Heparin-Conjugated Fibrin in the Posterolateral Lumbar Fusion of Rabbits

被引:20
|
作者
Koo, Ki-Hyoung [1 ]
Lee, Jong-Min [1 ]
Ahn, Jung-Min [1 ]
Kim, Byung-Soo [2 ,3 ]
La, Wan-Geun [2 ,3 ]
Kim, Chang-Sung [4 ]
Im, Gun-Il [1 ]
机构
[1] Dongguk Univ Ilsan Hosp, Dept Orthopaed Surg, Goyang 410773, South Korea
[2] Seoul Natl Univ, Sch Chem & Biol Engn, Seoul, South Korea
[3] Seoul Natl Univ, Inst Bioengn, Inst Chem Proc, Engn Res Inst, Seoul, South Korea
[4] Yonsei Univ, Coll Dent, Dept Periodontol, Seoul 120749, South Korea
关键词
Bone morphogenetic protein-2; Long-term delivery system; Heparin-conjugated fibrin; Spine fusion; Dose; CONTROLLED-RELEASE; SPINAL-FUSION; SUSTAINED DELIVERY; COLLAGEN SPONGE; RHBMP-2; EFFICACY; MODEL; REGENERATION; ARTHRODESIS; SYSTEM;
D O I
10.1111/j.1525-1594.2012.01578.x
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The heparin-conjugated fibrin (HCF) system has been developed to deliver bone morphogenetic proteins (BMPs) for a long-term period and thus enhance bone regeneration. In the present study, we tested the effectiveness of the delivery system for spinal fusion with a very low dose of BMP-2. A total of 15 rabbits underwent posterolateral lumbar spine, divided into three groups. The control group received only collagen sponges without BMP-2, another group (BMP-only group) received collagen sponges loaded with BMP-2 (10g each side), and the last group (BMP/HCF group) received collagen sponges filled with HCF loaded with BMP-2 (10g each side). All animals were euthanized 8 weeks after surgery, and the fusion was assessed by radiographs, manual palpation, computed tomography scan, and mechanical testing. No case in the BMP/HCF group or in the control group achieved solid fusion, while all cases in BMP-only group showed evidence of solid fusion. BMP/HCF group had significantly lower fusion rate and tensile strength than BMP-only group at the dose of 10g of BMP-2. The HCF long-term delivery system with the low dose of BMP-2 (10g) is ineffective for the induction of lumbar posterolateral fusion in the rabbits.
引用
收藏
页码:487 / 494
页数:8
相关论文
共 50 条
  • [21] Sex-based Difference in Response to Recombinant Human Bone Morphogenetic Protein-2 in a Rat Posterolateral Fusion Model
    Foley, James P.
    Fred, Elianna J.
    Minardi, Silvia
    Yamaguchi, Jonathan T.
    Greene, Allison C.
    Furman, Andrew A.
    Lyons, Joseph G.
    Paul, Jonathan T.
    Nandurkar, Tejas S.
    Blank, Kenneth R.
    Havey, Robert M.
    Muriuki, Muturi
    Patwardhan, Avinash G.
    Hsu, Wellington K.
    Stock, Stuart R.
    Hsu, Erin L.
    SPINE, 2022, 47 (23) : 1627 - 1636
  • [22] Allogeneic morphogenetic protein vs. recombinant human bone morphogenetic protein-2 in lumbar interbody fusion procedures: a radiographic and economic analysis
    Roh, Jeffrey S.
    Yeung, Christopher A.
    Field, Justin S.
    McClellan, R. Trigg
    JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2013, 8
  • [23] Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial
    Cho, Jae Hwan
    Lee, Jae Hyup
    Yeom, Jin Sup
    Chang, Bong-Soon
    Yang, Jae Jun
    Koo, Ki Hyoung
    Hwang, Chang Ju
    Lee, Kwang Bok
    Kim, Ho-Joong
    Lee, Choon-Ki
    Kim, Hyoungmin
    Suk, Kyung-Soo
    Nam, Woo Dong
    Han, Jumi
    SPINE JOURNAL, 2017, 17 (12) : 1866 - 1874
  • [24] Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study
    Lykissas, Marios G.
    Aichmair, Alexander
    Sama, Andrew A.
    Hughes, Alexander P.
    Lebl, Darren R.
    Cammisa, Frank P.
    Girardi, Federico P.
    SPINE JOURNAL, 2014, 14 (02) : 217 - 224
  • [25] Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2
    Patel, Zarana S.
    Yamamoto, Masaya
    Ueda, Hiroki
    Tabata, Yasuhiko
    Mikos, Antonios G.
    ACTA BIOMATERIALIA, 2008, 4 (05) : 1126 - 1138
  • [26] Injectable hydrogels embedded with alginate microspheres for controlled delivery of bone morphogenetic protein-2
    Zhu, Youjia
    Wang, Jiulong
    Wu, Jingjing
    Zhang, Jun
    Wan, Ying
    Wu, Hua
    BIOMEDICAL MATERIALS, 2016, 11 (02)
  • [27] Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy
    Alden, TD
    Pittman, DD
    Beres, EJ
    Hankins, GR
    Kallmes, DF
    Wisotsky, BM
    Kerns, KM
    Helm, GA
    JOURNAL OF NEUROSURGERY, 1999, 90 (01) : 109 - 114
  • [28] Effect of Bone Morphogenetic Protein-2 (BMP-2)/Hydroxyapatite/In Situ-Formed Hyaluronan Hydrogel Composites on Bone Formation in a Murine Model of Posterolateral Lumbar Fusion
    Kuroda, Akiyoshi
    Saito, Wataru
    Inoue, Gen
    Miyagi, Masayuki
    Shoji, Shintaro
    Sekiguchi, Hiroyuki
    Takaso, Masashi
    Uchida, Kentaro
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (05)
  • [29] Fusion rate of Escherichia coli -derived recombinant human bone morphogenetic protein-2 compared with local bone autograft in posterior lumbar interbody fusion for degenerative lumbar disorders
    Park, Sangman
    ha Jeong, Yeong
    Ha, Byeong Jin
    Yoo, Beom seok
    Kim, Soo-Heon
    Lee, Chang Kyu
    Yi, Seong
    Ha, Yoon
    Kim, Keung Nyun
    Shin, Dong Ah
    SPINE JOURNAL, 2023, 23 (12) : 1877 - 1885
  • [30] Recombinant human bone morphogenetic protein-2 versus autogenous iliac crest bone graft for lumbar fusion: a meta-analysis of ten randomized controlled trials
    Chen, Zhiguang
    Ba, Gen
    Shen, Tao
    Fu, Qin
    ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2012, 132 (12) : 1725 - 1740